Table 4. The percentage change of the cognitive decline by the end of the 10-year treatment period for the LMCI group.

Subject #	Starting at Age 60			Starting at Age 70
	Aducanumab		Donanemab	Aducanumab		Donanemab
	Low dose	High dose		Low dose	High dose
MCI1	3.4	5.1	15	0.33	0.49	1.2
MCI2	5.7	7.8	16	2.8	3.8	8.2
MCI3	4.6	6.9	18	0.55	0.83	2
MCI4	NR	NR	NR	NR	NR	NR
MCI5	0.12	0.19	0.53	2.5 × 10−5	3.3 × 10−5	4.3 × 10−5
MCI6	1.4 × 10−2	2.2 × 10−2	3.4 × 10−2	3.3 × 10−6	5.3 × 10−6	3.2 × 10−6
MCI7	1.9	2.7	5.7	1.3	1.9	4.2
MCI8	7.4	11	27	2.1	3.1	8.1
MCI9	0.12	0.17	0.32	1 × 10−2	1.8 × 10−2	2.9 × 10−2
MCI10	NR	NR	5.1 × 10−7	NR	NR	NR
MCI11	NR	NR	1.2 × 10−6	NR	NR	2.2 × 10−7
MCI12	1.1 × 10−7	5 × 10−7	5.7 × 10−6	NR	NR	3.5 × 10−7
MCI13	0.18	0.28	0.71	2.5 × 10−3	4 × 10−3	4.3 × 10−2
MCI14	3.6	5.4	15	0.26	0.4	0.88
MCI15	1.1	1.5	2.7	1.1	1.5	2.7
MCI16	1.8 × 10−7	2.9 × 10−7	1.9 × 10−6	NR	NR	NR
MCI17	0.89	1.6	6.5	4.2 × 10−4	5.9 × 10−4	1.5 × 10−3
MCI18	7.5 × 10−7	9.2 × 10−7	1.1 × 10−6	NR	NR	NR
MCI19	0.29	0.42	0.73	0.24	0.35	0.63
MCI20	7.3	9.8	19	4.9	6.5	13
MCI21	4	5.9	16	1	1.5	4.1
MCI22	4.3	5.8	11	3.3	4.5	9.1
MCI23	3.8 × 10−6	4.7 × 10−6	7.2 × 10−5	NR	NR	NR
MCI24	0.82	1.2	2.4	0.62	0.91	1.9
MCI25	NR	NR	NR	NR	NR	NR
MCI26	0.12	0.2	0.53	6.8 × 10−5	1 × 10−4	3.2 × 10−3
MCI27	6.3	9.3	24	1.7	2.5	6.6
MCI28	1.2	1.8	4	0.88	1.3	2.9
MCI29	9.1 × 10−5	1.5 × 10−4	1.4 × 10−3	NR	NR	NR
MCI30	21	31	55	8.8	14	31
MCI31	7.9	11	23	2.2	3.1	6.8
MCI32	9.2	13	27	3.5	5	11
Median	3.5	5.3	13	1.3	1.9	4.2